Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

被引：0

作者：

Phillips, R. ^{[1
]}

Proudfoot, J. ^{[2
]}

Davicioni, E. ^{[2
,3
]}

Spratt, D. E. ^{[4
]}

Feng, F. Y. ^{[5
]}

Simko, J. ^{[6
]}

Den, R. B. ^{[7
]}

Pollack, A. ^{[8
]}

Rosenthal, S. A. ^{[9
]}

Sartor, O. ^{[10
]}

Sweeney, C. ^{[11
]}

Attard, G. ^{[12
]}

Patel, S. I. ^{[13
]}

Hall, W. A. ^{[14
]}

Efstathiou, J. A. ^{[15
]}

Shah, A. B. ^{[16
]}

Hoffman, K. E. ^{[17
]}

Pugh, S. ^{[18
]}

Sandler, H. M. ^{[19
]}

Tran, P. T. ^{[20
]}

机构：

[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA

[2] Veracyte Inc, San Diego, CA USA

[3] Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA

[4] Case Western Reserve Univ, Cleveland, OH USA

[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA

[6] UCSF, San Francisco, CA USA

[7] Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll & Ctr Canc, Philadelphia, PA USA

[8] Miami Univ, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Sutter Med Grp & Canc Ctr, Sacramento, CA USA

[10] Tulane Univ, New Orleans, LA USA

[11] South Australian Immunogen Canc Inst, Adelaide, SA, Australia

[12] Inst Canc Res, London, England

[13] Univ Alberta, Div Radiat Oncol, Edmonton, AB, Canada

[14] Med ColI Wisconsin, Dept Radiat Oncol, Milwaukee, WI USA

[15] Harvard Med Sch, Dept Radiat Oncol, Boston, MA USA

[16] York Canc Ctr, York, PA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Breast Radiat Oncol, Houston, TX USA

[18] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

[19] Cedars Sinai Med Ctr, Los Angeles, CA USA

[20] Univ Maryland, Dept Radiat Oncol, Sch Med, Baltimore, MD USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

158

引用

页码：S34 / S35

页数：2

共 50 条

[21] Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).
McKenzie, M. R.
Chi, K. N.
Neville, A.
Ellard, S.
Baerg, B.
Ruether, D.
Winquist, E.
Segal, R.
Lukka, H.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 249S - 249S
[22] RADIOTHERAPY AND ANDROGEN ABLATION FOR CLINICALLY LOCALIZED HIGH-RISK PROSTATE-CANCER
POLLACK, A
ZAGARS, GK
KOPPLIN, S
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (01): : 13 - 20
[23] Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer
Nguyen, P. L.
Huang, H. C.
Davicioni, E.
Sandler, H. M.
Shipley, W. U.
Efstathiou, J. A.
Simko, J.
Pollack, A.
Dicker, A. P.
Roach, M.
Rosenthal, S. A.
Morginstin, M.
Mendez, L.
Hartford, A. C.
Hall, W. A.
Desai, A. B.
Rabinovitch, R.
Peters, C. A.
Rodgers, J.
Feng, F. Y.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S50 - S50
[24] Adjuvant Radiation, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of RTOG 0621
Hurwitz, M. D.
Zhang, Q.
Sartor, O.
Xiao, Y.
Shayegan, B.
Sperduto, P. W.
Badiozamani, K. R.
Lawton, C. A.
Horwitz, E. M.
Michalski, J. M.
Roof, K.
Beyer, D. C.
George, A.
Sandler, H. M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2
[25] What is the key factor determining effectiveness of radiotherapy for high-risk prostate cancer: a hidden message from RTOG 0521
Okamoto, Keisei
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (04) : 650 - 652
[26] Phase II trial of weekly docetaxel and complete androgen blockade prior to radical prostatectomy in high-risk localized prostate cancer patients
Font, Albert
Mellado, Begona
Aparicio, Luis A.
Gallardo, Enrique
Mel, Ramon
Alcaraz, Antonio
Areal, Juan
Gomez Veiga, Francisco J.
Hannaoui, Nahim
Gascon, Pere
ANNALS OF ONCOLOGY, 2006, 17 : 146 - 146
[27] Final Results of a Phase I Trial of Total Androgen Blockade, Weekly Docetaxel, and Image-guided Intensity Modulated Radiotherapy for Localized High-risk Prostate Cancer
Marshall, D. T.
Golshayan, A.
Kraft, A.
Chaudhary, U.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S395 - S395
[28] Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial
Oudard, S.
Latorzeff, I.
Caty, A.
Miglianico, L.
Sevin, E.
Bessard, A-C. Hardy
Delva, R.
Rolland, F.
Chevreau, C.
Priou, F.
Beuzeboc, P.
Gravis, G.
Linassier, C.
Gomez, P.
Voog, E.
Chinet, P.
Muracciole, X.
Jaillon, C. Abraham
Elaidi, R.
Culine, S.
ANNALS OF ONCOLOGY, 2017, 28
[29] Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer
Iwamoto, Hiroaki
Izumi, Kouji
Mizokami, Atsushi
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (07) : 1324 - 1326
[30] Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer
Nishiyama, Tsutomu
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2012, 129 (3-5): : 179 - 190

← 1 2 3 4 5 →